Roche, Glaxo add psychiatric behavior warnings to flu drugs

03/5/2008 | Guardian (London), The

Roche Holding and GlaxoSmithKline PLC -- manufacturers of Tamiflu and Relenza, respectively -- have placed new warnings regarding delirium and abnormal psychiatric behavior on the labels of their influenza medications. The FDA has reviewed reports of neuropsychiatric problems in some patients, primarily in Japan. The drugmakers, however, said on the labels that their drugs' link to these adverse reactions "has not been established."

View Full Article in:

Guardian (London), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC